Axon Enterprise (NASDAQ:AXON) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Axon Enterprise (NASDAQ:AXON) had its target price upped by stock analysts at JPMorgan Chase & Co. from $750.00 to $755.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 77.70% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Needham & Company LLC cut their price target on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. UBS Group set a $440.00 price objective on Axon Enterprise in a research note on Thursday. Barclays decreased their price objective on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $820.00 target price on shares of Axon Enterprise in a report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $722.69.

Axon Enterprise Stock Performance

NASDAQ:AXON traded up $39.02 during midday trading on Thursday, hitting $424.88. The company’s stock had a trading volume of 1,860,802 shares, compared to its average volume of 1,053,136. Axon Enterprise has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The firm has a market cap of $34.23 billion, a P/E ratio of 278.81, a P/E/G ratio of 8.12 and a beta of 1.44. The firm’s 50 day moving average is $452.24 and its 200-day moving average is $529.24.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.08 EPS. Equities analysts anticipate that Axon Enterprise will post 1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the sale, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the transaction, the chief executive officer owned 3,090,997 shares of the company’s stock, valued at approximately $1,546,240,339.28. This represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,855 shares of company stock valued at $7,109,828 in the last ninety days. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

Institutional investors have recently bought and sold shares of the business. Vicus Capital lifted its position in shares of Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 14 shares in the last quarter. Evergreen Capital Management LLC raised its position in Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 15 shares during the period. NorthCrest Asset Manangement LLC lifted its holdings in Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 16 shares in the last quarter. WPG Advisers LLC lifted its holdings in Axon Enterprise by 9.8% during the third quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 17 shares in the last quarter. Finally, Monte Financial Group LLC grew its position in shares of Axon Enterprise by 5.5% in the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 17 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q1 revenue and guidance lift — Axon reported Q1 revenue of about $807M (+33.7% Y/Y) and raised its full?year revenue growth outlook to roughly 30–32%, citing strong software and device demand. This beat and the guidance raise are the primary positive catalysts. Axon reports Q1 2026 revenue
• Positive Sentiment: AI and product momentum — Management highlighted very strong AI revenue (up ~700% Y/Y), software & services growth (~35% Y/Y), and large gains in counter?drone sales, underpinning faster recurring revenue and long?term ARR expansion. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analyst buy support — Multiple firms reiterated or maintained Buy ratings (William Blair, Needham) and some analysts kept sizable price targets (e.g., Needham $600), signaling continued sell?side confidence in Axon’s growth trajectory. Axon Earns Buy Rating
• Neutral Sentiment: Price target trims but still bullish — Citizens Jmp lowered its PT from $825 to $700 (still “market outperform”) and Piper Sandler trimmed its PT to $674 (still “overweight”). These cuts reduce upside expectations but left ratings intact, so they’re only a modest drag. Citizens Jmp price target cut
• Negative Sentiment: Margin/earnings pressure — Reports flagged an EPS miss (tariff?driven margin headwinds and a small EPS shortfall vs some estimates), which tempers the headline beat and is the primary near?term risk to multiple?expansion. AXON Q1 Earnings Miss Estimates
• Negative Sentiment: Short?term sell?side reaction mixed — Some coverage noted shares “slipped” in places despite the beat, reflecting investor focus on margins, valuation, and the recent YTD share price decline. Axon Shares Slip Despite Q1 Results

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.